Limits...
Prognostic and predictive values of long non-coding RNA LINC00472 in breast cancer.

Shen Y, Katsaros D, Loo LW, Hernandez BY, Chong C, Canuto EM, Biglia N, Lu L, Risch H, Chu WM, Yu H - Oncotarget (2015)

Bottom Line: Our qPCR results showed that high LINC00472 expression was associated with less aggressive breast tumors and more favorable disease outcomes.Patients with high expression of LINC00472 had significantly reduced risk of relapse and death compared to those with low expression.High LINC00472 was also associated with favorable molecular subtypes, Luminal A or normal-like tumors.

View Article: PubMed Central - PubMed

Affiliation: Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.

ABSTRACT
LINC00472 is a novel long intergenic non-coding RNA. We evaluated LINC00472 expression in breast tumor samples using RT-qPCR, performed a meta-analysis of over 20 microarray datasets from the Gene Expression Omnibus (GEO) database, and investigated the effect of LINC00472 expression on cell proliferation and migration in breast cancer cells transfected with a LINC00472-expressing vector. Our qPCR results showed that high LINC00472 expression was associated with less aggressive breast tumors and more favorable disease outcomes. Patients with high expression of LINC00472 had significantly reduced risk of relapse and death compared to those with low expression. Patients with high LINC00472 expression also had better responses to adjuvant chemo- or hormonal therapy than did patients with low expression. Results of meta-analysis on multiple studies from the GEO database were in agreement with the findings of our study. High LINC00472 was also associated with favorable molecular subtypes, Luminal A or normal-like tumors. Cell culture experiments showed that up-regulation of LINC00472 expression could suppress breast cancer cell proliferation and migration. Collectively, our clinical and in vitro studies suggest that LINC00472 is a tumor suppressor in breast cancer. Evaluating this long non-coding RNA in breast tumors may have prognostic and predictive value in the clinical management of breast cancer.

No MeSH data available.


Related in: MedlinePlus

Associations of LINC00472 expression with patient survival in turin studyA. Kaplan-Meier estimates for disease-free survival by LINC00472 expression. B. Kaplan-Meier estimates for overall survival by LINC00472 expression.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4496168&req=5

Figure 1: Associations of LINC00472 expression with patient survival in turin studyA. Kaplan-Meier estimates for disease-free survival by LINC00472 expression. B. Kaplan-Meier estimates for overall survival by LINC00472 expression.

Mentions: In the clinical study of 348 tumor samples, high LINC00472 expression occurred more often in patients with smaller tumors (p < 0.0001), lower tumor grades (p < 0.0001), and earlier stage disease (p = 0.007) (Table 1). Also, patients with positive hormone receptors had higher LINC00472 expression compared to those with negative receptor status (p < 0.0001 for ER or PR) (Table 1). Furthermore, patients with high expression had better responses to adjuvant chemotherapy (p = 0.021) and hormonal therapy (p = 0.003) than those with low expression (Table 1). Finally, survival analysis suggested that patients with high expression had better disease-free (p < 0.001) and overall survival (p = 0.005) compared to those with low expression (Figures 1A, 1B, and Table 2). Risk reduction in relapse was also observed when disease stage, tumor grade, receptor status and other clinical features of the patients were adjusted in analysis (p = 0.043) (Table 2).


Prognostic and predictive values of long non-coding RNA LINC00472 in breast cancer.

Shen Y, Katsaros D, Loo LW, Hernandez BY, Chong C, Canuto EM, Biglia N, Lu L, Risch H, Chu WM, Yu H - Oncotarget (2015)

Associations of LINC00472 expression with patient survival in turin studyA. Kaplan-Meier estimates for disease-free survival by LINC00472 expression. B. Kaplan-Meier estimates for overall survival by LINC00472 expression.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4496168&req=5

Figure 1: Associations of LINC00472 expression with patient survival in turin studyA. Kaplan-Meier estimates for disease-free survival by LINC00472 expression. B. Kaplan-Meier estimates for overall survival by LINC00472 expression.
Mentions: In the clinical study of 348 tumor samples, high LINC00472 expression occurred more often in patients with smaller tumors (p < 0.0001), lower tumor grades (p < 0.0001), and earlier stage disease (p = 0.007) (Table 1). Also, patients with positive hormone receptors had higher LINC00472 expression compared to those with negative receptor status (p < 0.0001 for ER or PR) (Table 1). Furthermore, patients with high expression had better responses to adjuvant chemotherapy (p = 0.021) and hormonal therapy (p = 0.003) than those with low expression (Table 1). Finally, survival analysis suggested that patients with high expression had better disease-free (p < 0.001) and overall survival (p = 0.005) compared to those with low expression (Figures 1A, 1B, and Table 2). Risk reduction in relapse was also observed when disease stage, tumor grade, receptor status and other clinical features of the patients were adjusted in analysis (p = 0.043) (Table 2).

Bottom Line: Our qPCR results showed that high LINC00472 expression was associated with less aggressive breast tumors and more favorable disease outcomes.Patients with high expression of LINC00472 had significantly reduced risk of relapse and death compared to those with low expression.High LINC00472 was also associated with favorable molecular subtypes, Luminal A or normal-like tumors.

View Article: PubMed Central - PubMed

Affiliation: Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.

ABSTRACT
LINC00472 is a novel long intergenic non-coding RNA. We evaluated LINC00472 expression in breast tumor samples using RT-qPCR, performed a meta-analysis of over 20 microarray datasets from the Gene Expression Omnibus (GEO) database, and investigated the effect of LINC00472 expression on cell proliferation and migration in breast cancer cells transfected with a LINC00472-expressing vector. Our qPCR results showed that high LINC00472 expression was associated with less aggressive breast tumors and more favorable disease outcomes. Patients with high expression of LINC00472 had significantly reduced risk of relapse and death compared to those with low expression. Patients with high LINC00472 expression also had better responses to adjuvant chemo- or hormonal therapy than did patients with low expression. Results of meta-analysis on multiple studies from the GEO database were in agreement with the findings of our study. High LINC00472 was also associated with favorable molecular subtypes, Luminal A or normal-like tumors. Cell culture experiments showed that up-regulation of LINC00472 expression could suppress breast cancer cell proliferation and migration. Collectively, our clinical and in vitro studies suggest that LINC00472 is a tumor suppressor in breast cancer. Evaluating this long non-coding RNA in breast tumors may have prognostic and predictive value in the clinical management of breast cancer.

No MeSH data available.


Related in: MedlinePlus